Document Page: First | Prev | Next | All | Image | This Release | Search

File: aaaau_02.txt
Page: 02
Total Pages: 2

ROUTINE                                   UNCLASSIFIED


PAGE 02 OF 02    RHDJGAA 1009                       003888     16/0049Z
IN LOW MALARIA THREAT AREAS.
;B) CHLOROQUINE PHOSPHATE 500 MG (300 MG BASE) (ONE BY  MOUTH  EACH
WEEK STARTED TWO WEEKS PRIOR TO EXPOSURE, CONTINUED WEEKLY DURING
EXPOSURE, AND FOR SIX-TO-EIGHT WEEKS POST EXPOSURE).  CHLOROQUINE
RESISTANT MALARIA IS NOT A PROBLEM IN POTENTIAL OPERATIONAL AREAS.
;3) IF NO MALARIA HAZARD AREA WAS ENTERED, INDIVIDUAL SHOULD RETURN
THEIR MALARIA PROPHYLAXIS TO THE ISSUER.
THE MEDICAL PERSONNEL IN THE AOR WILL BE THE AUTHORITY FOR
DESIGNATING A MALARIA HAZARD AREA AND MAY AUTHORIZE INDIVIDUALS  TO
STOP (OR START) TAKING MALARIA PROPHYLAXIS.
(4) IF MALARIA HAZARD AREA WAS ENTERED, THEN NORMAL TERMINAL
PROPHYLAXIS OF EIGHT, WEEKLY DOSES OF 45 MG PRIMAOUINE SHOULD BE
ISSUED, IN ADDITION TO CONTINUING DOXYCYCLINE OR CHLOROQUINE,
FOLLOWING RETURN TO CONUS.  (OVALE AND/OR VIVAX-MALARIA  ARE  PRESENT
IN AOR MALARIA AREAS).
2. MENINGOCOCCAL IMMUNIZATION (QUADRAVALENT, A/C/Y/WI35, NSN 6505 01
2865312) SHOULD BE BROADENED TO INCLUDE ALL DEPLOYING PERSONNEL  AS
SUPPLIES ALLOW.  LACK OF MENINGOCOCCAL IMMUNIZATION WITHIN 5 YEARS
SHOULD NOT BE CONSIDERED A DETRIMENT TO DEPLOYMENT OF NONMEDICAL
PERSONNEL.
3. POINT OF CONTACT IS MAJ PHILIP A. LA KIEN, NGB/SGP DSN 858-8550.
BT
#1009








                                      UNCLASSIFIED


Document Page: First | Prev | Next | All | Image | This Release | Search